一分钟看懂
这是一项关于急性髓系白血病的I 期研究，登记的药物或干预包括LP-108；Azacitidine，当前状态为招募中。登记地点显示中国南昌、苏州、郑州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
LP-108；Azacitidine · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of Nanchang University · 南昌
- First Affiliated Hospital of Soochow University · 苏州
- Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital · 郑州
公开的入选条件
- * Subject must has a diagnosis of one of the following: relapsed or refractory (R/R) or untreated ineligible for treatment with a standard induction chemotherapy acute myeloid leukemia (AML) ; R/R myelodysplastic syndrome(MDS) or untreated MDS with excess blas
- * ECOG performance status ≤ 2.
- * Estimated survival ≥ 12 weeks.
- * Baseline white blood cell count (WBC) ≤ 25 x 109/L.
- * Subject must has adequate organ function as defined below: Aspartate transaminase (AST) and alanine transaminase (ALT)≤3 x ULN; Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin); adequate renal function as dem
- * Prior treatment-related toxicities must be grade 1 or baseline except for alopecia.
- * If subject is sexually active, he/she must agree to carry out birth control throughout the study and 90 days after the last dose of LP-108. Subject must agree to have a negative serum β-HCG test result within 7 days prior to study drug.
- * Subject must voluntarily sign and date an informed consent.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05641259；登记信息更新于 2026-09-11。